504-75-6

Usage

Uses

4,5-Dihydro-1H-imidazole possesses inhibition effect on the crevice corrosion of N80 carbon steel; Also, it is derived from Formamide (F691480), which is a compound that is used in biochemistry to prevent RNA samples from degradation due to RNAses. Formamide is also used as a plasticizer to prepare thermoplastic starch (TPS), a special type of starch that can be mixed with other synthetic polymers because of its unique ability to “flow”.

Definition

ChEBI: An imidazoline compound having the double bond at the 2-position.

InChI:InChI=1/C3H6N2/c1-2-5-3-4-1/h3H,1-2H2,(H,4,5)

Synthetic route

N,N'-ethylenethiourea (96-45-7) → 2-imidazoline (504-75-6) + imidazolidone (120-93-4)

Conditions	Yield
With 3,3-dimethyldioxirane In methanol; acetone at 25℃;	A 53% B 15%

carbon monoxide (201230-82-2) + ethylenediamine (107-15-3) → 2-imidazoline (504-75-6) + imidazolidone (120-93-4) + N-β-aminoethylcarbamic acid (109-58-0)

Conditions	Yield
With tetracarbonyl nickel In ethanol at 160℃; for 18h;	A 28% B 10.6% C 31.7%
With tetracarbonyl nickel In ethanol at 160℃; for 18h;	A 28% B 10.6% C 31.7%

1,3,5-Triazine (290-87-9) + ethylenediamine (107-15-3) → 2-imidazoline (504-75-6)

N,N'-ethylenethiourea (96-45-7) → 2-imidazoline (504-75-6) + imidazolidone (120-93-4) + 4,5-dihydro-1H-imidazole-2-sulfonic acid (64205-92-1)

Conditions	Yield
With dihydrogen peroxide; trifluoroacetic acid at 25℃;

2-imidazoline (504-75-6) + N-butyl-2-iodobenzamide → C14H17N3O (1362191-54-5) + C14H15N3O (1362191-28-3)

Conditions	Yield
Stage #1: 2-imidazoline; N-butyl-2-iodobenzamide With caesium carbonate; L-proline In dimethyl sulfoxide for 0.333333h; Ullmann reaction; Inert atmosphere; Stage #2: With copper(l) iodide In dimethyl sulfoxide at 120℃; for 12h; Ullmann reaction; Inert atmosphere;	A 88% B n/a

2-imidazoline (504-75-6) + molybdenum hexacarbonyl (13939-06-5, 199620-15-0) → cis-tetracarbonylbis(2-imidazoline-N)molybdenum(0) (64121-72-8) + fac-tricarbonyltris(2-imidazoline-N)molybdenum(0) (64121-75-1)

Conditions	Yield
In toluene byproducts: CO; N2-atmosphere; 3 equiv. of imidazoline, 100°C, 10 min (pptn.); filtration, washing (Et2O), drying (vac.); elem. anal.; bis(imidazoline)-complex from filtrate;	A 20% B 75%

2-imidazoline (504-75-6) + 2-methyl-5-[4-hydroxy-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-4,5-dihydro-1H-imidazol-2-yl]pyridine (177662-53-2) → 2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine (177660-80-9)

Conditions	Yield
With p-toluenesulfonic acid monohydrate In ethyl acetate; acetone; toluene	66%

thirane (420-12-2) + 2-imidazoline (504-75-6) → 2-imidazolinylethanethiol

Conditions	Yield
In toluene for 48h; Heating;	62%

2-imidazoline (504-75-6) + di-μ-chloro-bis(1,5-cyclooctadiene)dirhodium (12092-47-6) → chloro(cyclo-octa-1,5-diene)(2-imidazoline-N)rhodium(I) (67012-40-2)

Conditions	Yield
In toluene N2-atmosphere; stoich. amts., refluxing for 1 h; crystn. (-20°C), addn. of hexane, collection (filtration), washing (Et2O), drying (vac.); elem. anal.;	55%

2-imidazoline (504-75-6) + 4-[4-hydroxy-1-[4-(methylsulfonyl) phenyl]-4-(trifluoromethyl)-4,5-dihydro-1H-imidazol-2-yl]pyridine (177662-51-0) → 4-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (177660-79-6)

Conditions	Yield
With p-toluenesulfonic acid monohydrate In ethyl acetate; acetone; toluene	41%

2-imidazoline (504-75-6) + 7-methoxy-1H-isochromene-1,3(4H)-dione (4702-29-8) → (10R,10aR)-1-[2-(2-Carboxy-4-methoxy-phenyl)-acetyl]-7-methoxy-5-oxo-1,2,3,5,10,10a-hexahydro-imidazo[1,2-b]isoquinoline-10-carboxylic acid

Conditions	Yield
In acetonitrile at 0℃; for 2h;

2-imidazoline (504-75-6) + 4-(4-fluorophenoxy)benzonitrile (215589-24-5) → 2-[4-(4-Fluorophenoxy)phenyl]-1H-imidazole (299206-79-4)

Conditions	Yield
With hydrogenchloride; sodium hydroxide; p-toluenesulfonic acid monohydrate; ethylenediamine; palladium-carbon In methanol; ethylene glycol; ethyl acetate; toluene

2-imidazoline (504-75-6) + 4-ethylphenacyl bromide (2632-14-6) → 1-(4-ethylphenyl)-2-imidazolylethan-1-one (1094655-78-3)

Conditions	Yield
In acetonitrile

2-imidazoline (504-75-6) + CH3 + triethylamine (121-44-8) → 1H-imidazole (288-32-4)

Conditions	Yield
With manganese dioxide In dichloromethane; chloroform	370 mg (76%)
With manganese dioxide In dichloromethane; chloroform	370 mg (76%)

2-imidazoline (504-75-6) + 4-[2-Imidazolin-2-yl]-6-(2-chlorophenyl)-2,3,4,5-tetrahydro-8H-[1]benzothieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine + N,N-dimethyl-formamide (68-12-2, 33513-42-7) + methyl iodide (74-88-4) → 4-[1-Methyl-2-imidazolin-2-yl]-6-(2-chlorophenyl)-2,3,4,5-tetrahydro-8H-[1]benzothieno[3,2-f][1,2,4]triazolo [4,3-a][1,4]diazepine

Conditions	Yield
In tetrahydrofuran

2-imidazoline (504-75-6) + 3-methyl-6-[4-hydroxy-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-4,5-dihydro-1H-imidazol-2-yl]pyridine (189297-36-7) → 5-methyl-2-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine (177660-82-1)

Conditions	Yield
With p-toluenesulfonic acid monohydrate In toluene

2-imidazoline (504-75-6) + amoxicillin (26787-78-0) → N-[6-[[2-(acetylamino)-1-oxopropyl]amino]-1,4-dihydro-4-oxo-3-quinolinylcarbonyl]amoxicillin

Conditions	Yield
With sodium hydroxide; triethylamine In N,N-dimethyl acetamide; water

2-imidazoline (504-75-6) → 1-acetyl-2-imidazoline (87604-75-9)

Conditions	Yield
In ethanol; acetic anhydride
In ethanol; acetic anhydride
In ethanol; acetic anhydride

Upstream product

• 290-87-9 1,3,5-Triazine 
• 107-15-3 ethylenediamine 
• 96-45-7 N,N'-ethylenethiourea 
• 201230-82-2 carbon monoxide 

Downstream Products

• 1094655-78-3 1-(4-ethylphenyl)-2-imidazolylethan-1-one 
• 288-32-4 1H-imidazole 
• 177660-79-6 4-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine 
• 177660-80-9 2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine 
• 1362191-54-5 C₁₄H₁₇N₃O 
• 1362191-28-3 C₁₄H₁₅N₃O 
• 177660-82-1 5-methyl-2-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine 
• 299206-79-4 2-[4-(4-Fluorophenoxy)phenyl]-1H-imidazole 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS

Methods are provided for the treatment of osteoporosis and multiple myeloma, using 3-imidazoyl-pyrazolo[3,4-b]pyridine compounds.

NOVEL AROMATIC COMPOUND AND POLYARYLENE COPOLYMER HAVING NITROGEN-CONTAINING HETEROCYCLE INCLUDING SULFONIC ACID GROUP IN SIDE CHAIN

Provided is a solid polymer electrolyte having increased heat resistance and high proton conductivity and a proton conductive membrane composed of the electrolyte. Also provided is a copolymer having a sulfonic acid group. The copolymer includes a repeating unit represented by Formula (1): (in the formula, Y denotes at least one kind of structure selected from the group consisting of —CO—, —SO2—, —SO—, —CONH—, —COO—, —(CF2)l— (l is an integer of 1 to 10), and —C(CF3)2—; W denotes at least one kind of structure selected from the group consisting of a direct bond, —CO—, —SO2—, —SO—, —CONH—, —COO—, —(CF2)l— (l is an integer of 1 to 10), —C(CF3)2—, —O—, and —S—; Z denotes a direct bond or at least one kind of structure selected from the group consisting of —(CH2)l—(l is an integer of 1 to 10), —C(CH3)2—, —O—, —S—, —CO—, and —SO2—; R30 denotes a nitrogen-containing aromatic ring having a substituent represented by —SO3H, —O(CH2)hSO3H, or —O(CF2)hSO3H (h is an integer of 1 to 12); p is an integer of 0 to 10; q is an integer of 0 to 10; r is an integer of 1 to 5; and k is an integer of 0 to 4).

OXIDIZED AND MALEATED DERIVATIVE COMPOSITIONS

Oxidized and maleated derivative compositions, such as chemically modified oxidized and maleated tall oil fatty acid compositions, can be prepared and used in a variety of industrial applications, including as emulsifiers, corrosion inhibitors, concrete admixtures, and in reverse flotation mining applications.

Pyridoxine and pyridoxal analogues: new uses

The invention provides pyridoxal and pyridoxine analogues, pharmaceutical compositions containing pyridoxine and pyridoxal analogues, and methods of administering pharmaceutical compositions containing a therapeutically effective amount of at least one of these analogues. In accordance with the present invention, the pyridoxal and pyridoxine analogues can be used in the treatment or prevention of of heparin induced thrombocytopenia (HIT, stroke, and ischemia, and in the treatment of symptoms thereof. The the pyridoxal and pyridoxine analogues can be used in neuroprotection.

Pyridoxine and pyridoxal analogues: new uses

The invention provides pyridoxal and pyridoxine analogues, pharmaceutical compositions containing pyridoxine and pyridoxal analogues, and methods of administering pharmaceutical compositions containing a therapeutically effective amount of at least one of these analogues. In accordance with the present invention, the pyridoxal and pyridoxine analogues can be used in the treatment or prevention of of heparin induced thrombocytopenia (HIT, stroke, and ischemia, and in the treatment of symptoms thereof. The the pyridoxal and pyridoxine analogues can be used in neuroprotection.

BETA-SHEET MIMETICS AND METHODS RELATING TO THE USE THEREOF

beta -sheet mimetics and methods relating to the same are disclosed. The beta -sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a beta -sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.

Pyridoxine and pyridoxal analogues: novel uses

The invention provides pyridoxal and pyridoxine analogues, pharmaceutical compositions containing pyridoxine and pyridoxal analogues, and methods of administering pharmaceutical compositions containing a therapeutically effective amount of at least one of these analogues. In accordance with the present invention, the pyridoxal and pyridoxine analogues can be used in the treatment of undesired platelet aggregation, and in the treatment of symptoms thereof.

Hypoglycemic imidazoline compounds

This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.

Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics

The invention provides pyridoxal and pyridoxine analogues, pharmaceutical compositions containing pyridoxine and pyridoxal analogues, and methods of administering pharmaceutical compositions containing a therapeutically effective amount of at least one of these analogues. In accordance with the present invention, the pyridoxal and pyridoxine analogues can be used in the treatment of cardiovascular or related diseases and in the treatment of symptoms thereof.

BETA-SHEET MIMETICS AND THEREOF AS PROTEASE INHIBITORS

There are disclosed β-sheet mimetics and methods relating to the same for imparting or stabilizing the β-sheet structure of a peptide, protein or molecule. In one aspect, the β-sheet mimetics are covalently attached at the end or within the length of the peptide or protein. The β-sheet mimetics have utility as protease inhibitors generally, including activity as serine protease inhibitors such as thrombin, elastase and Factor X.